AstraZeneca and its global biologics research and development arm, MedImmune, announced that the Committee for Medicinal Products for Human Use...
Seqirus announced that the FDA has approved Audenz (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted) to help protect individuals six months...
Pfizer and MedImmune ( a subsidiary of AstraZeneca) will collaborate to develop tremelimumab. The drug was unsuccessful in a Phase...
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Zoonotic Influenza Vaccine Seqirus, intended for the active immunisation against H5N1 subtype of Influenza A virus.
GSK has received a Complete Response Letter from the FDA for its pandemic influenza A vaccine, called Q-Pan H5N1. Q-PAN...
The FDA has approved FluMist Quadrivalent,from Medimmune a vaccine to prevent seasonal influenza in people ages 2 years through 49...
GSK has submitted a regulatory application to the FDA seeking approval for an H5N1 influenza vaccine. The Biologics License Application...
The FDA has approved Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (also referred to as Q-Pan H5N1 influenza vaccine), from...
AstraZeneca has announced that MedImmune, its global biologics research and development arm, has entered into a licensing agreement with Omnis...